GSK’s Jesduvroq is claimed to be the only HIF-PHI approved in the US. Credit: GSK plc.

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s (GSK) Jesduvroq (daprodustat) to treat anaemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least four months.

Jesduvroq is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is claimed to be the only HIF-PHI approved in the country that offers a new oral treatment option for adult patients on dialysis with anaemia of CKD.

GSK president and chief scientific officer Tony Wood said: “Over the last several decades, there has been little innovation in anaemia of CKD.

“We are proud to have developed Jesduvroq as a new oral treatment where there is a patient desire for more options.”

The regulatory approval is based on the data obtained from the ASCEND-D trial, which is evaluating Jesduvroq’s safety and efficacy to treat patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The ASCEND programme included five Phase III trials that enrolled more than 8,000 patients who received treatment for up to 4.26 years.

Findings demonstrated that daprodustat improved or maintained the Hb in target levels (10g/dL-11.5g/dL) for the patients.

It also achieved non-inferiority of MACE compared to ESA control, in the primary safety analysis of the ITT population.

In June 2020, Japan’s Ministry of Health, Labour and Welfare approved daprodustat tablets to treat patients with anaemia of CKD.

The European Medicines Agency is currently reviewing a marketing authorisation application for daprodustat and a regulatory decision is expected in the first half of this year.

Last December, GSK and Wave Life Sciences entered a strategic partnership to drive the discovery and development of oligonucleotide therapies for new genetic targets.